Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph A Tripp

Showing results (21-30 of 238) with videos related to

Pageof 24
Sort By:
Expert Opinion on Investigational Drugs|September 9, 2024
Antiviral agents and therapeutics against respiratory virusesRalph A Tripp, David E Martin
Vaccines|July 15, 2020
Pathobiology of Respiratory Syncytial Virus (RSV)Ralph A Tripp, Paul S McNamara
Expert Opinion on Biological Therapy|April 9, 2020
Up-to-date role of biologics in the management of respiratory syncytial virusSeyhan Boyoglu-Barnum, Ralph A Tripp
Expert Opinion on Investigational Drugs|December 23, 2021
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)Harrison C Bergeron, Ralph A Tripp
Current Topics in Microbiology and Immunology|September 22, 2009
Animal models for evaluation of influenza vaccinesRalph A Tripp, S Mark Tompkins
Current Topics in Microbiology and Immunology|June 25, 2017
Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) InfectionRalph A Tripp, Abhijeet A Bakre
Expert Review of Respiratory Medicine|June 3, 2017
Respiratory syncytial virus: prospects for new and emerging therapeuticsPatricia A Jorquera, Ralph A Tripp
Plos One|August 4, 2020
Exosome-mediated human norovirus infectionKyle V Todd, Ralph A Tripp
Methods in Molecular Biology (Clifton, N.J.)|June 5, 2009
Therapeutic applications of RNAi for silencing virus replicationRalph A Tripp, Stephen Mark Tompkins
Viruses|April 17, 2020
Vero Cells as a Mammalian Cell Substrate for Human NorovirusKyle V Todd, Ralph A Tripp
Pageof 24

Showing results (21-30 of 238) with videos related to

Sort By:
Pageof 24
Expert Opinion on Investigational Drugs|September 9, 2024
Antiviral agents and therapeutics against respiratory virusesRalph A Tripp, David E Martin
Vaccines|July 15, 2020
Pathobiology of Respiratory Syncytial Virus (RSV)Ralph A Tripp, Paul S McNamara
Expert Opinion on Biological Therapy|April 9, 2020
Up-to-date role of biologics in the management of respiratory syncytial virusSeyhan Boyoglu-Barnum, Ralph A Tripp
Expert Opinion on Investigational Drugs|December 23, 2021
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)Harrison C Bergeron, Ralph A Tripp
Current Topics in Microbiology and Immunology|September 22, 2009
Animal models for evaluation of influenza vaccinesRalph A Tripp, S Mark Tompkins
Current Topics in Microbiology and Immunology|June 25, 2017
Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) InfectionRalph A Tripp, Abhijeet A Bakre
Expert Review of Respiratory Medicine|June 3, 2017
Respiratory syncytial virus: prospects for new and emerging therapeuticsPatricia A Jorquera, Ralph A Tripp
Plos One|August 4, 2020
Exosome-mediated human norovirus infectionKyle V Todd, Ralph A Tripp
Methods in Molecular Biology (Clifton, N.J.)|June 5, 2009
Therapeutic applications of RNAi for silencing virus replicationRalph A Tripp, Stephen Mark Tompkins
Viruses|April 17, 2020
Vero Cells as a Mammalian Cell Substrate for Human NorovirusKyle V Todd, Ralph A Tripp
Pageof 24